In conclusion, the localization of PSMA expression in the neovasculature of thyroid carcinoma instead of in tumor cells as in prostate carcinoma might explain why 177Lu-PSMA treatment is less effective in DTC than in prostate carcinoma. This evidence concerns the gene FOLH1 and thyroid gland carcinoma.